Bullish
$AIMT with only 8 months of lead time before competition hits the pavement Aimmune should have been to the high volume immunologists. They all know about the new therapies that are coming out but they haven’t had any direction in regards to disease state education. In a normal launch environment they would have already been out to dinner for educational programs in every city. No company launches with just MSL’s- they launch with everyone in place before so that the staff and prescribers understand day one after approval. Either this is a big show and a buyout is in place or they just don’t understand that 8 months of lead time goes by extremely fast and market share could be wiped out.
  • 2